Stocktoria
Tempus AI, Inc. TEM
Tempus AI, Inc. (TEM) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 0.06% (safety: no dividend). FY2025 revenue was $1.3B at a -19.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-04 | Piper Sandler | Neutral (main) |
| 2026-08-03 | BTIG | Buy (main) |
| 2026-08-03 | HC Wainwright & Co. | Buy (main) |
| 2026-08-03 | Stifel | Hold (main) |
| 2026-07-31 | Needham | Buy (reit) |
| 2026-07-20 | Needham | Buy (reit) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.349 |
| Retained earnings / assets | -1.053 |
| EBIT / assets | -0.111 |
| Equity / liabilities | 0.275 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TEM | Tempus AI, Inc. | 3/9 | -1.6 | — | +83.4% |
| LAWR | Robot Consulting Co., Ltd. | 2/9 | — | — | +60.6% |
| BZ | Kanzhun Ltd | 4/9 | 9.8 | — | +17.3% |
| BMBL | Bumble Inc. | 4/9 | -5.26 | — | -9.9% |
| HUYA | HUYA Inc. | 3/9 | 4.77 | — | +11.6% |
| DOCN | DigitalOcean Holdings, Inc. | 7/9 | -0.21 | 56.1 | +15.5% |
| WB | WEIBO Corp | 5/9 | 5.3 | 31 | +0.1% |
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
FAQ
Is TEM financially healthy?
Tempus AI, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does TEM pay a dividend, and is it safe?
Yes. Tempus AI, Inc. pays a dividend yielding about 0.06% with a None payout ratio, rated “no dividend” for safety.
How profitable is TEM?
In FY2025, Tempus AI, Inc. had a net margin of -19.3% and a return on equity of -49.9%.
What is the analyst price target for TEM?
The average Wall-Street price target for Tempus AI, Inc. is $62.64, about 14.7% above the recent price, from 14 analysts (consensus: buy).
Is TEM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Tempus AI, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone, a dividend yield of 0.06%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.